The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D

Cancer Letters

Volumn 100, Issue 1-2, 1996, Pages 71-79

  Wieder, Thomas ^a   Zhang, Zu Chuan ^b,c   Geilen, Christoph C ^a   Orfanos, Constantin E ^a   Giuliano, Armando E ^b   Cabot, Myles C ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Antitumor lipid; Hexadecylphosphocholine; Phospholipase D; Second messengers

Indexed keywords

1 HEXADECYL 2 METHYLGLYCEROPHOSPHOCHOLINE; CELL ENZYME; CHOLINE; DIACYLGLYCEROL; ENZYME ACTIVATOR; LYSOPHOSPHATIDYLCHOLINE; MILTEFOSINE; PHORBOL DIBUTYRATE; PHOSPHOLIPASE D; PHOSPHOLIPID DERIVATIVE; PROTEIN KINASE C INHIBITOR; STAUROSPORINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LABELING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVATION; FIBROBLAST; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; ISOTOPE LABELING; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0030020318     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(95)04072-2     Document Type: Article

References (36)

1. Berdel, W.E., Andreesen, R. and Munder, P.G. (1985) Synthetic alkyl-phospholipid analogues; a new class of antitumor agents. In: Phospholipids and Cellular Regulation, Vol. 2, pp. 41-73. Editor: J.F. Kuo. CRC Press, Boca Raton, FL.
2. Okamoto, S., Olson, A.C. and Vogler, W.R. (1987) Elimination of leukemic cells by the combined use of ether lipids in vitro. Cancer Res., 47, 2599-2603.
3. Unger, C., Fleer, E.A.M., Kötting, J., Neumüller, W. and Eibl, H. (1992) Antitumoral activity of alkylphosphocholines and analogues in human leukemia cell lines. Prog. Exp. Tumor Res., 34, 25-32.
4. Hilgard, P., Stekar, J., Voegeli, R., Engel, J., Schuhmacher, W., Eibl, H., Unger, C. and Berger, M.R. (1988) Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). Eur. J. Cancer Clin. Oncol., 24, 1457-1461.
5. Unger, C., Damenz, W., Fleer, E.A.M., Kim, D.J., Breiser, A., Hilgard, P., Engel, J., Nagel, G. and Eibl, H. (1989) Hexadecylphosphocholine, a new ether lipid analog. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol., 28, 213-217.
6. Eibl, H. and Unger, C. (1990) Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev., 17, 233-242.
7. 3 and hexadecylphosphocholine against mammary tumors in BD-V1 rats. Lipids, 22, 927-929.
8. van Blitterswijk, W.J., van der Bend, RL., Kramer, I.J. Verhoeven, A.J., Hilkmann, H. and de Widt, J. (1987) A metabolite of an antineoplastic ether phospholipid may inhibit transmembrane signaling via protein kinase C. Lipids, 22, 842-846.
9. Nakamura, S., Asaoka, Y., Yoshida, K., Sasaki, Y. and Nishizuka, Y. (1993) Protein kinase C for cell signaling: a possible link between phospholipases. In: Advances in Second Messenger and Phosphorylation Research, Vol. 28, p. 171-178. Editors: B.L. Brown and P.R.M. Dobson. Raven Press, New York.
10. Überall, F., Oberhuber, H., Maly, K., Zaknun, J., Demuth, L. and Grunicke, H.H. (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res., 51, 807-812.
11. Geilen, C.C., Haase, R., Buchner, K., Wieder, Th., Hucho, F. and Reutter, W. (1991) The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation. Eur. J. Cancer, 27, 1650-1653.
12. Zheng, B., Oishi, K., Shoji, M., Eibl, H., Berdel, W.E., Hajdu, J., Vogler, W.R. and Kuo, J.F. (1990) Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphate and sodium pump by synthetic phospholipid analogues. Cancer Res., 50, 3025-3031.
13. Haase, R., Wieder, Th., Geilen, C.C. and Reutter, W. (1991) The phospholipid analogue hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells. FEBS Lett., 288, 129-132.
14. Geilen, C.C., Wieder, Th. and Reutter, W. (1991) Hexadecylphosphocholine inhibits translocation of CTP:cholinephosphate cytidylyltransferase in Madin-Darby canine kidney cells. J. Biol. Chem., 267, 6719-6724.
15. Geilen, C.C., Wieder, Th., Haase, A., Reutter, W., Morré, D.M. and Morré, D.J. (1994) Uptake, subcellular distribution and metabolism of the phospholipid analogue hexadecylphosphocholine in MDCK cells. Biochim. Biophys. Acta, 1211, 14-22.
16. 14C]choline. J. Labelled Comp. Radiopharm., 31, 1071-1076.
17. Bligh, E.G. and Dyer, W.J. (1959) A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol., 137, 911-917.
18. Huang, C. and Cabot, M.C. (1990) Phorbol diesters stimulate the accumulation of phosphatidate, phosphatidylethanol, and diacylglycerol in three cell types: evidence for the indirect formation of phosphatidylcholine-derived diacylglycerol by a phospholipase D pathway and direct formation of diacylglycerol by a phospholipase C pathway. J. Biol. Chem., 265, 14858-14863.
19. Huang, C., Wykle, R.L., Daniel, L.W. and Cabot, M.C. (1992) Identification of phosphatidylcholine-selective and phosphatidylinositol-selective phospholipases D in Madin-Darby canine kidney cells. J. Biol. Chem., 267, 16859-16865.
20. Huang, C. and Cabot, M.C. (1990) Vasopressin-induced polyphosphoinositide and phosphatidylcholine degradation in fibroblasts: temporal relationships for formation of phospholipase C and phospholipase D hydrolysis products. J. Biol. Chem., 265, 17468-17473.
21. Liscovitch, M. (1992) Signal-dependent activation of phosphatidylcholine hydrolysis: role of phospholipase D. Biochem. Soc. Trans. 19, 402-408.
22. Asaoka, Y., Nakamura, S., Yoshida, K. and Nishizuka, Y. (1992) Protein kinase C, calcium and phospholipid degradation. Trends Biochem. Sci., 17, 414-418.
23. Exton, J.H. (1990) Signaling through phosphatidylcholine breakdown. J. Biol Chem., 265, 1-4.
24. Ha, K.-S., Yeo, E.-J. and Exton, J.H. (1994) Lysophosphatidic acid activation of phosphatidylcholine-hydrolysing phospholipase D and actin polymerization by a pertussis toxin-sensitive mechanism. Biochem. J., 303, 55-59.
25. Cabot, M.C., Welsh, C.J. and Snyder, F. (1982) Increasing the levels of ether-linked lipids in L-M cells by glyceryl ether supplementation depresses growth and choline utilization. Biochim. Biophys. Acta, 713, 11-22.
26. Chabot, M.C. Wykle, R.L., Modest, E.J. and Daniel, L.W. (1989) Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Cancer Res., 49, 4441-4445.
27. Vance, D.E. (1990) Phosphatidylcholine metabolism; masochistic enzymology metabolic regulation and lipoprotein assembly. Biochem. Cell Biol., 68, 1151-1165.
28. Tidwell, T., Guzman, G. and Vogler, W.R. (1981) The effects of alkyl-lysophospholipids on leukemic cell lines. I. Differential action on two human leukemic cell lines, HL-60 and K-562. Blood, 57, 794-797.
29. 3 acts as an activator of protein kinase C in HL-60 cells. FEBS Lett., 290, 231-234.
30. ++ dependent protein kinase. Biochem. Biophys. Res. Commun., 135, 397-402.
31. Cabot, M.C., Welsh, C.J., Zhang, Z.C. and Cao, H.T. (1989) Evidence for a protein kinase C-directed mechanism in the phorbol diester-induced phospholipase D pathway of diacylglycerol generation from phosphatidylcholine. FEBS Lett., 245, 85-90.
32. Oishi, K., Raynor, R.C., Charp, P.A. and Kuo, J.F. (1988) Regulation of protein kinase C by lysophospholipids. J. Biol. Chem., 263, 6865-6871.
33. Spector, A.A. and Yorek, M.A. (1985) Membrane lipid composition and cellular function. J. Lipid Res., 26, 1015-1035.
34. Spector, A.A. and Burns, C.P. (1987) Biological and therapeutic potential of membrane lipid modification in tumors. Cancer Res., 471 4529-4537.
35. Letourneur, F. and Klausner, R.D. (1992) Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 ε. Science 255, 79-82.
36. Lohmeyer, M. and Bittman, R. (1994) Antitumor ether lipids and alkylphosphocholines. Drugs Future, 19, 1021-1037.